Breaking News Instant updates and real-time market news.

MCD

McDonald's

$193.93

-2.71 (-1.38%)

, ADSK

Autodesk

$150.18

(0.00%)

09:40
11/04/19
11/04
09:40
11/04/19
09:40

Unusually active option classes on open November 4th

Unusual total active option classes on open include: McDonald's (MCD), Autodesk (ADSK), Qualcomm (QCOM), Bausch Health (BHC), General Electric (GE), Walgreen Boots (WBA), Fitbit (FIT), Facebook (FB), iShares Emerging Markets ETF (EEM), and Uber (UBER).

MCD

McDonald's

$193.93

-2.71 (-1.38%)

ADSK

Autodesk

$150.18

(0.00%)

QCOM

Qualcomm

$83.58

(0.00%)

BHC

Bausch Health

$25.92

(0.00%)

GE

General Electric

$10.38

0.4 (4.01%)

WBA

Walgreens Boots Alliance

$57.36

(0.00%)

FIT

Fitbit

$7.12

(0.00%)

FB

Facebook

$193.68

(0.00%)

EEM

iShares MSCI Emerging Markets ETF

$43.23

0.01 (0.02%)

UBER

Uber

$31.27

-0.05 (-0.16%)

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 06

    Nov

  • 06

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 21

    Nov

  • 22

    Nov

  • 26

    Nov

  • 02

    Dec

  • 04

    Dec

  • 29

    Jan

MCD McDonald's
$193.93

-2.71 (-1.38%)

11/04/19
MKMP
11/04/19
NO CHANGE
Target $225
MKMP
Buy
McDonald's price target lowered to $225 from $240 at MKM Partners
MKM Partners analyst Brett Levy lowered his price target on McDonald's to $225 after its abrupt announcement of a CEO change over the weekend. The analyst notes while the developments surrounding the transition may not impact results, the company may suffer from a "psychological impact" and the stock could see some near-term pressure. Levy adds that McDonald's has been under pressure for a couple of months now, and the transition will not "ease any recent concerns".
11/04/19
SPHN
11/04/19
NO CHANGE
Target $225
SPHN
Overweight
McDonald's shares attractive on the pullback, says Stephens
The departure of CEO Steve Easterbrook is a "fairly significant negative" for investors, given his history of impressive and consistent global results, Stephens analyst Will Slabaugh tells investors in a research note. The analyst, however, likes the "quick choice" of Chris Kempczinski as the next CEO, given his existing relationships with domestic operators and "leadership experience during some of the U.S.'s best years in decades." Slabaugh likes McDonald's here and views the shares as attractive on the recent pullback. He keeps an Overweight rating on the name with a $225 price target. McDonald's in premarket trading is down 3%, or $5.09, to $188.85.
11/04/19
FBCO
11/04/19
NO CHANGE
Target $230
FBCO
Outperform
Credit Suisse views any pullback in McDonald's stock as buying opportunity
Credit Suisse analyst Lauren Silberman tells investors in a research note that she thinks McDonald's shares could be under "modest" pressure Monday after the company announced that Steve Easterbrook has separated from the company following the board's determination that he violated company policy and demonstrated poor judgment involving a recent consensual relationship with an employee. Easterbrook was "highly regarded" in the investment community and among franchisees, and potential concerns of franchisee sentiment regarding new leadership, Silberman says, but adds that McDonald's has a "talented" bench and expects management and the board have a like-minded strategy. She says the management transition does not alter her positive view of the company, and views any material pullback pullback in the stock around the CEO change as a buying opportunity. Silberman maintains an Outperform rating and $230 price target.
11/04/19
LEHM
11/04/19
NO CHANGE
Target $225
LEHM
Overweight
McDonald's should be bought on weakness from CEO change, says Barclays
While the CEO transition announced by McDonald's was unexpected, "and therefore not a good thing," the change was not due to operational or financial issues, but rather personal conduct, Barclays analyst Jeffrey Bernstein tells investors in a research note. The analyst is confident the company has the depth in leadership to maintain momentum as the global quick service restaurant leader. As such, he's a buyer of McDonald's shares on any weakness and keeps an Overweight rating on the name with a $225 price target.
ADSK Autodesk
$150.18

(0.00%)

08/28/19
WELS
08/28/19
NO CHANGE
Target $180
WELS
Outperform
Autodesk price target lowered to $180 from $200 at Wells Fargo
Wells Fargo analyst Philip Winslow lowered his price target for Autodesk to $180 from $200 after the company delivered "strong" Q2 results, but with management deciding to take a more cautious approach to the business outlook for the second half of the fiscal year, despite believing global macroeconomic uncertainties and trade disputes will be short-term. The analyst reiterates an Outperform rating on the shares.
08/28/19
08/28/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Autodesk (ADSK) downgraded to Underperform from Neutral at BofA/Merrill with analyst Kash Rangan saying while the company posted solid July quarter results, uncertainty has increased as its fiscal 2020 guidance was lowered across the board. 2. Antero Midstream (AM) downgraded to Market Perform from Outperform at Raymond James. 3. Catalent (CTLT) downgraded to Sector Weight from Overweight at KeyBanc with analyst Donald Hooker saying he believes free cash flow will be limited at 20%-30% of EBITDA due to heavy capital spending, and the company will be carrying a high debt ratio, both of which may limit flexibility. 4. Kelly Services (KELYA) downgraded to Neutral from Buy at Northcoast with analyst John Healy saying shares are approaching his liquidation value of around $26. 5. Nabors Industries (NBR), Nine Energy Services (NINE), and Quintana Energy Services (QES) downgraded to Neutral from Buy at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/28/19
BARD
08/28/19
NO CHANGE
Target $177
BARD
Outperform
Autodesk weakness a buying opportunity, says Baird
Baird analyst Rob Oliver expects Autodesk shares to open lower following its Q2 results and he believes investors who step in at these levels have a favorable 12-month upside. The analyst said the disappointing guidance provided the entry point and he lowered his price target as well. He said manufacturing weighed on the company outlook but strength in other areas provided confidence in its updated outlook. Oliver maintained his Outperform rating and lowered his price target to $177 from $185 on Autodesk shares.
08/28/19
FBCO
08/28/19
NO CHANGE
Target $175
FBCO
Outperform
Autodesk price target lowered to $175 from $188 at Credit Suisse
Credit Suisse analyst Brad Zelnick lowered his price target for Autodesk to $175 from $188 after the company reported "solid" results for Q2 but guided down the second half of the year, citing FX headwinds and uncertainty in manufacturing in Germany, U.K., China. While the analyst anticipates the near-term focus will be on the guide down and the potential risk for another cut, he believes investors should focus on the long-term opportunity in construction. He reiterates an Outperform rating on the shares.
QCOM Qualcomm
$83.58

(0.00%)

08/21/19
MSCO
08/21/19
NO CHANGE
Target $89
MSCO
Overweight
Qualcomm, LG pact validates view FTC ruling 'irrelevant,' says Morgan Stanley
Morgan Stanley analyst James Faucette said Qualcomm's new five year agreement with LG validates his previously expressed view that Judge Koh's ruling in the FTC case is "largely irrelevant" to Qualcomm's ability to collect royalties and to their underlying economics. If either party felt like it had substantial position to gain from the 9th Circuit's eventual ruling, he does not see it as likely that an agreement would have been reached now, added Faucette, who keeps an Overweight rating and $89 price target on Qualcomm shares.
10/09/19
ADAM
10/09/19
NO CHANGE
Target $87
ADAM
Buy
Qualcomm near-term softness expected ahead of 5G ramp, says Canaccord
Canaccord analyst T. Michael Walkley said iPhone strength combined with soft global Android smartphone demand and ongoing China smartphone weak trends, will result in weak near-term results for Qualcomm. This is consistent with company guidance but the analyst remains positive long-term as he believes the company is well positioned to benefit from the transition to 5G. Walkley reiterated his Buy rating and $87 price target on Qualcomm shares.
08/26/19
MZHO
08/26/19
NO CHANGE
Target $68
MZHO
Neutral
Qualcomm scores legal victory with appeal, says Mizuho
Qualcomm on Friday scored a victory in its Ninth Circuit Court appeal, with the court granting the company a partial stay of the FTC's motion pending appeal, Mizuho analyst Vijay Rakesh tells investors in a research note. The analyst believes the partial stay is a near-term positive since Qualcomm does not have to renegotiate license and patent deals while the appeal is in process. However, near-term China uncertainty has increased with President Trump raising tariffs for September 1, adds Rakesh. He keeps a Neutral rating on shares of Qualcomm with a $68 price target.
09/17/19
ATLE
09/17/19
NO CHANGE
ATLE
Skyworks mentioned cautiously at Arete Research
Arete believes Qualcomm (QCOM) will replace Skyworks (SWKS) at Samsung, contacts tell The Fly.
BHC Bausch Health
$25.92

(0.00%)

09/17/19
WELS
09/17/19
NO CHANGE
WELS
Underperform
Wells says two of Bausch's 'Significant Seven' not on UnitedHealth benefit list
Wells Fargo analyst David Maris noted that United Healthcare (UNH) released its Pharmacy Benefit Coverage update, which shows that as of January 2020 it is excluding Bausch Health's (BHC) Bryhali, which he said is one of the company's "Significant Seven" focus products. Another of the Significant Seven, Siliq, will no longer be covered under UnitedHealth's pharmacy benefit plans, said Maris. Two other Significant Seven members - Vyzulta and Relistor - are listed as required step therapy and needing a prior authorization, respectively, Maris added. The analyst, who thinks Bausch Health's pipeline and recently approved products are "unimpressive," keeps an Underperform rating on the stock. Reference Link
09/11/19
GUGG
09/11/19
INITIATION
GUGG
Buy
Bausch Health initiated with a Buy at Guggenheim
Guggenheim analyst Dana Flanders initiated Bausch Health with a Buy rating and a $30 price target, citing the company's strong execution and the durability of its businessses. Flanders believes Bausch will lower its $27B in debt over the next few years, which "should translate to a double-digit compounded equity return for shareholders."
10/25/19
COWN
10/25/19
INITIATION
Target $35
COWN
Outperform
Bausch Health initiated with an Outperform at Cowen
Cowen analyst Ken Cacciatore initiated coverage of Bausch Health with an Outperform rating as he believes management has successfully transformed and is slowly strengthening its portfolio. The company is also launching new products across the key B&L, Salix, and Dermatological segments while growing its Xifaxan franchise. Cacciatore has a $35 price target on Bausch Health shares.
10/03/19
PIPR
10/03/19
NO CHANGE
Target $29
PIPR
Overweight
Bausch unlikely to face generic Xifaxan before 2028, says Piper Jaffray
Piper Jaffray analyst David Amsellem says he would not be worried that a generic Xifaxan entrant will emerge prior to the January 2028 launch date outlined in Bausch Health Companies' (BHC) settlement with Teva (TEVA) on its generic filing. The analyst highlights the "relatively complex nature" of Xifaxan and Bausch's "fairly deep intellectual property estate." As such, he continues to believe that visibility into a "durable" EBITDA for Bausch Health is high, with a longer-term annual growth "reaching at least the high single digits." He reiterates an Overweight rating on the shares with a $29 price target.
GE General Electric
$10.38

0.4 (4.01%)

11/04/19
LEHM
11/04/19
NO CHANGE
Target $12
LEHM
Overweight
Investors may start looking at GE with bull case becoming clearer, says Barclays
General Electric's Q3 contained "no nasty surprises" from legacy liabilities along with "some clear signs of progress amidst the house-cleaning," Barclays analyst Julian Mitchell tells investors in a research note. The analyst believes this will likely cause more long-term investors to start to take a closer look at GE during the second year of CEO Larry Culp's tenure. With GE's free cash flow bull case becoming clearer, long-term investors may start to take a look, says Mitchell. The analyst keeps an Overweight rating on General Electric shares with a $12 price target. The stock closed Friday up 40c to $10.38.
10/04/19
JPMS
10/04/19
NO CHANGE
Target $5
JPMS
Underweight
Investors are underestimating the risks at GE Aviation, says JPMorgan's Tusa
Following an "in depth review of structural dynamics around the fundamentals and financials," JPMorgan analyst Stephen Tusa stands by his view that GE Aviation "offers materially less growth with greater risk, and therefore less value support, than consensus assumes." Headwinds from a decline in high margin spare engines and negative mix in aftermarket are being underappreciated, Tusa tells investors in a research note. Further, the analyst sees "less capital cushion than many assume" for GE Aviation. The Aviation balance sheet "seems too small" in the context of cash already booked to take on its share of debt and pension burden, which limits GE's strategic options, contends Tusa. While Aviation is not Power, investors "over-estimate the sustainability of growth while under-estimating risks," concludes the analyst. He keeps an Underweight rating on GE shares with a $5 price target. The stock closed Thursday up 20c to $8.71.
10/31/19
DBAB
10/31/19
NO CHANGE
Target $11
DBAB
Hold
General Electric price target raised to $11 from $9 at Deutsche Bank
Deutsche Bank analyst Nicole DeBlase raised her price target for General Electric to $11 from $9 saying the company's Q3 results had more positives than negatives. Although Power segment results disappointed, it was overshadowed by several key positives, including GE maintaining its full year earnings guidance despite a 5c per share headwind from the deconsolidation of Baker Hughes (BHGE). The company also raised full year Industrial free cash flow guidance by $1B, adds DeBlase. The analyst keeps a Hold rating on General Electric.
11/01/19
JPMS
11/01/19
NO CHANGE
Target $5
JPMS
Underweight
JPMorgan's Tusa says GE results don't change view, price target remains $5
JPMorgan analyst Stephen Tusa says there is no change to his view of General Electric coming away from the Q3 results. "At a simplified headline level, there was no smoking gun, though the underlying details show a situation that is far from low risk," Tusa tells investors in a post-earnings research note. The analyst points out that even at the high end of GE's new free cash flow range, or a base of 23c per share, its free cash flow yield is 2%. This suggests that "stability is already more than discounted," says Tusa, who keeps an Underweight rating on General Electric with a $5 price target. The stock closed Thursday down 13c to $9.98.
WBA Walgreens Boots Alliance
$57.36

(0.00%)

09/27/19
RBCM
09/27/19
INITIATION
Target $59
RBCM
Sector Perform
Walgreens Boots Alliance assumed with a Sector Perform at RBC Capital
RBC Capital analyst Anton Hie assumed coverage of Walgreens Boots Alliance with a Sector Perform rating and a price target of $59. The analyst is positive on the company's "strong national presence" and sees its efforts to leveraged its partners' expertise to broaden its capabilities as a smart move. However, Hie does not expect Walgreens shares to reach "significantly higher" multiples until the management offers a more specific strategic direction and evidence of "strong progress" with a higher earnings trajectory.
10/23/19
JPMS
10/23/19
DOWNGRADE
Target $63
JPMS
Neutral
Walgreens Boots Alliance downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Lisa Gill downgraded Walgreens Boots Alliance to Neutral from Overweight with a $63 price target.
10/23/19
JPMS
10/23/19
DOWNGRADE
Target $63
JPMS
Neutral
JPMorgan downgrades Walgreens to Neutral ahead of fiscal 2020 outlook
JPMorgan analyst Lisa Gill downgraded Walgreens Boots Alliance to Neutral from Overweight with a price target of $63, down from $73. The analyst, based on her relative rating methodology, sees better opportunities for upside in other companies within her coverage universe at the current time. With Walgreens expected to provide fiscal 2020 guidance with Q4 results on October 28, its adjusted operating profit growth "will continue to remain challenged" in the near term, after a high-single digit decline in fiscal 2019, Gill tells investors in a pre-earnings research note. The analyst says that with growth taking longer to realize under the current strategy and limited clarity on the roadmap to improvement and few identifiable near term catalysts, she finds it difficult to justify on Overweight rating on Walgreens shares.
10/23/19
10/23/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Walgreens Boots Alliance (WBA) downgraded to Neutral from Overweight at JPMorgan with analyst Lisa Gill saying she based on her relative rating methodology, seeing better opportunities for upside in other companies within her coverage universe at the current time. 2. Cheniere Energy Partners (CQP) downgraded to Underperform at Raymond James with analyst Justin Jenkins saying that while his firm's North American energy macro outlook remains favorable for exporters from a supply-push perspective, he sees this as priced into Cheniere shares. 3. Resideo (REZI) downgraded to Perform from Outperform at Oppenheimer with analyst Ian Zaffino saying the company, once again, revised guidance negatively. 4. ServiceNow (NOW) downgraded to Neutral from Buy at Mizuho with analyst Gregg Moskowitz saying the company last night surprisingly announced the impending departure of CEO John Donahoe, who is going to head Nike (NKE), and lowered its full year guidance due to currency. 5. Kohl's (KSS) downgraded to In Line from Outperform at Evercore ISI. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
FIT Fitbit
$7.12

(0.00%)

11/04/19
DADA
11/04/19
DOWNGRADE
Target $7.35
DADA
Neutral
Fitbit downgraded to Neutral from Buy at DA Davidson
DA Davidson analyst Tom Forte downgraded Fitbit (FIT) to Neutral from Buy with a price target of $7.35, up from $5.75, after the company agreed to be acquired by Google (GOOGL). The analyst notes that while the deal may get some scrutiny from regulators, he is also encouraged that it is "finally" receiving "much deserved" attention for its healthcare-related business.
11/04/19
SBSH
11/04/19
UPGRADE
Target $7.35
SBSH
Neutral
Fitbit upgraded to Neutral from Sell at Citi
Citi analyst Jim Suva upgraded Fitbit (FIT) to Neutral from Sell with a price target of $7.35, up from $2.00. The analyst cites the takeover by Alphabet (GOOGL) for the upgrade to Neutral as he believes the acquisition will likely occur. He does not see any antitrust hurdles nor additional bidders.
11/01/19
MSCO
11/01/19
UPGRADE
Target $7.35
MSCO
Equal Weight
Fitbit upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley analyst Katy Huberty upgraded Fitbit (FIT) to Equal Weight from Underweight with a price target of $7.35, up from $3.20, after the company agreed to be acquired by Google (GOOGL).
11/01/19
ROTH
11/01/19
DOWNGRADE
Target $7.35
ROTH
Neutral
Fitbit downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Scott Searle downgraded Fitbit (FIT) to Neutral from Buy with a price target of $7.35, down from $8.00, after the company agreed to be acquired by Google (GOOGL). He sees the formal approval process and customary closing conditions "being ceremonial" and he does not expect an additional bidder. Searle also said he view Fitbit as a good fit for Google and thinks the monetization strategy for unique data in consumer and vertical healthcare markets will be "greatly accelerated" under the search giant's ownership.
FB Facebook
$193.68

(0.00%)

11/04/19
SOCG
11/04/19
NO CHANGE
Target $120
SOCG
Sell
Facebook regulatory compliance costs continue to rise, says Societe Generale
The costs of tighter regulation are kicking in at Facebook (FB), this time in the form of higher capital expenditure guidance next year, as the company addresses a "tornado of privacy, security and regulatory issues," Societe Generale analyst Simon Baker tells investors in a research note following last week's Q3 results. The analyst prefers shares of Alphabet (GOOG) and reiterates a Sell rating on Facebook with a $120 price target. Facebook's earnings beats over the last two years compare with a 50:50 record for Alphabet, and yet Alphabet shares have outperformed Facebook's by 17%, Baker points out.
11/01/19
MKMP
11/01/19
NO CHANGE
Target $210
MKMP
Neutral
Arista Networks price target lowered to $210 from $275 at MKM Partners
MKM Partners analyst Michael Genovese lowered his price target on Arista Networks (ANET) to $210 and kept his Neutral rating after is "scary bad guidance" for Q4 and 2020. The analyst attributes the disappointing forecast to the "sudden" slowing in orders from Facebook (FB), which is delaying the refresh of its Switches and Routers by a year.
11/01/19
NEED
11/01/19
DOWNGRADE
NEED
Hold
Arista Networks downgraded to Hold from Buy at Needham
Needham analyst Alex Henderson downgraded Arista Networks (ANET) to Hold from Buy after its "weak" Q4 guidance, saying this marks the 3rd consecutive quarter of a cut in outlook. The analyst notes that while the prior delay in orders from Microsoft (MSFT) has now come back, another larger customer - "most likely" Facebook (FB) - has sharply reduced its orders from Arista over the span of multiple quarters. Henderson adds that the reduction in outlook, along with the "unpredictability" of cloud demand, are likely to hurt valuations even when demand recovers.
11/01/19
COWN
11/01/19
NO CHANGE
Target $212
COWN
Outperform
Arista Networks price target lowered to $212 from $295 at Cowen
Cowen analyst Paul SIlverstein lowered his price target on Arista Networks (ANET) to $212 from $295 following Q3 results. The analyst significantly reduced his operating forecasts to reflect the painful impact of the delayed Facebook (FB) server refresh and he acknowledged it will take time for the company to regain investor confidence. Silverstein maintained his Outperform rating on Arista Networks shares.
EEM iShares MSCI Emerging Markets ETF
$43.23

0.01 (0.02%)

UBER Uber
$31.27

-0.05 (-0.16%)

10/25/19
10/25/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Essa Pharma (EPIX) initiated with an Outperform at Oppenheimer. 2. Uber (UBER) initiated with a Buy at Guggenheim. 3. LogMeln (LOGM) assumed with a Sector Perform at RBC Capital. 4. MannKind (MNKD) initiated with an Overweight at Cantor Fitzgerald. 5. Sanderson Farms (SAFM) initiated with an Underperform at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/28/19
DBAB
10/28/19
NO CHANGE
Target $29
DBAB
Hold
Uber launch could drive adoption of Green Dot powered card, says Deutsche Bank
Deutsche Bank analyst Ashish Sabadra said the launch of Uber Money (UBER) could drive greater adoption of the Uber debit card, which is powered by Green Dot (GDOT). Since there are no monthly fees for the debit card account, Sabadra thinks the primary monetization will be through interchange and other fees. The analyst keeps a Hold rating on Green Dot shares with a $29 price target.
10/31/19
GSCO
10/31/19
UPGRADE
Target $58
GSCO
Buy
Lyft upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Heath Terry upgraded Lyft (LYFT) to Buy from Neutral with a price target of $58, down from $71. The stock in premarket trading is up 4%, or $1.92, to $46.03. The company reported better than expected Q3 revenue and management noted a trend toward higher prices across the industry, incremental engagement per rider, and a less promotional competitive environment, Terry tells investors in a research note. Lyft continues to gain share and is beginning to show the operational efficiencies, says the analyst, who believes the stock's risk/reward is favorable at current levels. Lyft competitor Uber Technologies (UBER) is trading up 15c to $33.90.
10/25/19
NRCS
10/25/19
NO CHANGE
NRCS
Neutral
Northcoast checks show 'healthy' ride-hailing conditions during Q3
Northcoast analyst John Healy says his Q3 channel checks into ride-hailing conditions in the U.S. market indicate a backdrop that was "healthy at the margin with no meaningful slowdown." Further, Uber Technologies (UBER) seemed to win some of the "tug-of-war battle" between itself and Lyft (LYFT), as drivers seemed "marginally more pleased" with their time spent with Uber, Healy tells investors in a research note. He believes that at the margin, drivers during Q3 moved a bit more of their usage towards Uber. Meanwhile, Lyft continues to "inch pricing higher" for rides in many markets, while Uber is taking a more wait and see approach, says Healy. The analyst raised his Q3 earnings per share estimate for Lyft to (61c) from (72c), and lowered his Q3 estimate for Uber to (65c) from (63c). Healy keeps a Neutral rating on both stocks, but sees Lyft as the "cleaner/pure play story and at the margin more attractive."

TODAY'S FREE FLY STORIES

COO

Cooper Companies

$304.54

2.52 (0.83%)

08:22
12/11/19
12/11
08:22
12/11/19
08:22
Conference/Events
Cooper Companies management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

XLV

Health Care Select Sector SPDR

$99.86

0.14 (0.14%)

08:22
12/11/19
12/11
08:22
12/11/19
08:22
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$162.58

0.11 (0.07%)

08:22
12/11/19
12/11
08:22
12/11/19
08:22
Technical Analysis
iShares Trust Russell 2000 Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HDS

HD Supply

$39.07

-0.97 (-2.42%)

08:21
12/11/19
12/11
08:21
12/11/19
08:21
Recommendations
HD Supply analyst commentary  »

HD Supply price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIA

Diamonds Fund ETF

$279.48

-0.26 (-0.09%)

08:21
12/11/19
12/11
08:21
12/11/19
08:21
Technical Analysis
Diamonds Fund ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$313.58

-0.29 (-0.09%)

08:21
12/11/19
12/11
08:21
12/11/19
08:21
Technical Analysis
SPDR S&P 500 ETF Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNQ

Canadian Natural

$29.51

0.4524 (1.56%)

08:21
12/11/19
12/11
08:21
12/11/19
08:21
Upgrade
Canadian Natural rating change  »

Canadian Natural upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

XLF

Financial Select Sector

$30.28

(0.00%)

08:21
12/11/19
12/11
08:21
12/11/19
08:21
Technical Analysis
Financial Select Sector: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMH

Market Vectors Semiconductor

$133.61

0.51 (0.38%)

08:20
12/11/19
12/11
08:20
12/11/19
08:20
Technical Analysis
Market Vectors Semiconductor: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QQQ

Invesco QQQ Trust

$203.90

-0.13 (-0.06%)

08:20
12/11/19
12/11
08:20
12/11/19
08:20
Technical Analysis
Invesco QQQ Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$COMP

Nasdaq Composite

$0.00

(0.00%)

08:20
12/11/19
12/11
08:20
12/11/19
08:20
Technical Analysis
Nasdaq Composite: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LITE

Lumentum

$68.90

-0.73 (-1.05%)

, T

AT&T

$38.07

0.025 (0.07%)

08:20
12/11/19
12/11
08:20
12/11/19
08:20
Conference/Events
Barclays to hold a conference »

Global Technology, Media…

LITE

Lumentum

$68.90

-0.73 (-1.05%)

T

AT&T

$38.07

0.025 (0.07%)

GLW

Corning

$28.00

-0.5 (-1.75%)

AIC

Aames Investment

$23.46

0.055 (0.24%)

AMD

AMD

$39.44

0.53 (1.36%)

NOW

ServiceNow

$266.94

-2.95 (-1.09%)

ADSK

Autodesk

$178.50

-0.28 (-0.16%)

PEGA

Pegasystems

$75.42

-0.81 (-1.06%)

TXN

Texas Instruments

$121.38

-0.61 (-0.50%)

ALRM

Alarm.com

$41.80

-1.11 (-2.59%)

ESTC

Elastic

$62.46

0.32 (0.51%)

FICO

Fair Isaac

$354.61

-4.75 (-1.32%)

RVLV

Revolve Group

$17.02

-0.14 (-0.82%)

ZS

Zscaler

$46.10

-1.24 (-2.62%)

MOBL

MobileIron

$4.54

-0.045 (-0.98%)

AVLR

Avalara

$72.00

-0.84 (-1.15%)

VMW

VMware

$148.73

-0.78 (-0.52%)

CCC

Clarivate Analytics

$16.90

-0.17 (-1.00%)

MSFT

Microsoft

$151.18

-0.17 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

  • 12

    Dec

  • 16

    Dec

  • 16

    Dec

  • 08

    Jan

  • 10

    Jan

  • 29

    Jan

  • 05

    Mar

NDX

Nasdaq 100 Index

$0.00

(0.00%)

08:20
12/11/19
12/11
08:20
12/11/19
08:20
Technical Analysis
Nasdaq 100 Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PMBC

Pacific Mercantile Bancorp

$7.19

0.06 (0.84%)

08:19
12/11/19
12/11
08:19
12/11/19
08:19
Hot Stocks
Pacific Mercantile Bank provides financing to Mako Steel »

Pacific Mercantile Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCOM

Qualcomm

$84.11

-0.83 (-0.98%)

, AAPL

Apple

$268.62

1.69 (0.63%)

08:18
12/11/19
12/11
08:18
12/11/19
08:18
Recommendations
Qualcomm, Apple analyst commentary  »

BofA says Apple could…

QCOM

Qualcomm

$84.11

-0.83 (-0.98%)

AAPL

Apple

$268.62

1.69 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

DARE

Dare Bioscience

$0.80

-0.0087 (-1.08%)

08:15
12/11/19
12/11
08:15
12/11/19
08:15
Hot Stocks
Dare announces alignment with FDA on Phase 2b study of Sildenafil Cream »

Dare Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:15
12/11/19
12/11
08:15
12/11/19
08:15
General news
CPI to be reported at 08:30 »

November CPI will be…

08:15
12/11/19
12/11
08:15
12/11/19
08:15
General news
CPI less food & energy- to be reported at 08:30 »

November CPI less food…

ITRM

Iterum Therapeutics

$4.90

1.1 (28.95%)

08:14
12/11/19
12/11
08:14
12/11/19
08:14
Recommendations
Iterum Therapeutics analyst commentary  »

Iterum Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YEXT

Yext

$13.70

-0.685 (-4.76%)

08:14
12/11/19
12/11
08:14
12/11/19
08:14
Conference/Events
Yext management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

KLR

Kaleyra

$8.49

0.03 (0.35%)

08:11
12/11/19
12/11
08:11
12/11/19
08:11
Initiation
Kaleyra initiated  »

Kaleyra initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WINT

Windtree Therapeutics

$0.00

(0.00%)

08:11
12/11/19
12/11
08:11
12/11/19
08:11
Conference/Events
Windtree Therapeutics to hold a financial update »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSTM

Constellium

$14.50

0.06 (0.42%)

08:11
12/11/19
12/11
08:11
12/11/19
08:11
Hot Stocks
Constellium's Singen facility to offer ASI certified aluminum rolled solutions »

Constellium SE announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLSS

Milestone Scientific

$1.57

-0.03 (-1.88%)

08:10
12/11/19
12/11
08:10
12/11/19
08:10
Hot Stocks
Milestone Scientific partners with RedOne Medical to distribute CompuFlo »

Milestone Scientific…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

08:10
12/11/19
12/11
08:10
12/11/19
08:10
General news
U.S. CPI preview: w »

U.S. CPI preview:…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.